Sign In
Buy ENDO
$0.0001
+0 (+0%)
At Close: Jun 23, 2026
Participants who resumed VYKAT XR following a 16-week randomized withdrawal period demonstrated improvements in hyperphagia and behavioral symptoms as early as Week 13, with benefits continuing throug
Androstenedione and other adrenal hormone levels in 11β‑hydroxylase-deficient patients improved substantially after initiation of CRENESSITY, with >90% median reductions in 11-deoxycortisol and 11-
– ETHY-001 produced complete blockade of autoantibody-mediated TSHR activation across all patient serum samples tested, demonstrating breadth and consistency of effect –
The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026
Two-year data showed that pediatric patients with accelerated bone age at baseline experienced slowed bone age progression and improved predicted adult height with CRENESSITY Cross-sectional caregiver
Two-year CRENESSITY data in adults showed improvements in cardiometabolic outcomes of insulin resistance, body composition and body weight alongside sustained reductions in glucocorticoid dose Among p
Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026
01:57am, Monday, 15'th Jun 2026
Asedebart is an investigational monoclonal antibody designed to neutralize excess adrenocorticotropic hormone (ACTH) and reduce downstream cortisol production in Cushing's disease (CD) Urinary free co
Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms
– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in
Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
03:00am, Wednesday, 10'th Jun 2026
Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026 PR Newswire VAL
Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
02:19am, Wednesday, 10'th Jun 2026
Upcoming presentations at ENDO 2026 highlight Lundbeck's Focused Innovator strategy and continued expansion into rare neuroendocrine diseases with high unmet medical needs The scientific program showc
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
04:59pm, Monday, 08'th Jun 2026
COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achon
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
09:00am, Monday, 08'th Jun 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026.
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
07:00am, Monday, 08'th Jun 2026
Late-breaking presentation reports a proteomic analysis of heart failure biomarkers during lorundrostat treatment Late-breaking presentation reports a proteomic analysis of heart failure biomarkers du
